|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM064819353 |
| 003 |
DE-627 |
| 005 |
20231221230550.0 |
| 007 |
tu |
| 008 |
231221s1984 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0216.xml
|
| 035 |
|
|
|a (DE-627)NLM064819353
|
| 035 |
|
|
|a (NLM)6504947
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Young, J H
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Comparison of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol ('Moducren') given once versus twice daily in mild to moderate hypertension
|
| 264 |
|
1 |
|c 1984
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.01.1985
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a An open, multi-centre study was carried out in general practice to compare the efficacy and tolerance of antihypertensive therapy with once-daily and twice-daily dosage of a fixed ratio combination of hydrochlorothiazide (25 mg), amiloride (2.5 mg) and timolol (10 mg). A total of 604 patients with mild to moderate hypertension were treated over a period of 12 weeks with either 1 to 2 tablets once-daily (294 patients) or 1/2 to 1 tablet twice-daily (310 patients). The results showed that there was a significant reduction in systolic and diastolic blood pressures in both groups after only 2-weeks' therapy and the overall reduction after 12 weeks was 31/19 mmHg, with 57% of patients being adequately controlled on the equivalent of 1 tablet per day, whether taken once daily or in divided doses. Forty-six (8%) patients withdrew from the study because of drug-related symptoms, mainly central nervous system in origin. Overall, treatment with either regimen was considered suitable and acceptable by over 80% of patients and doctors
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Drug Combinations
|2 NLM
|
| 650 |
|
7 |
|a Pyrazines
|2 NLM
|
| 650 |
|
7 |
|a Hydrochlorothiazide
|2 NLM
|
| 650 |
|
7 |
|a 0J48LPH2TH
|2 NLM
|
| 650 |
|
7 |
|a moducrin
|2 NLM
|
| 650 |
|
7 |
|a 73788-01-9
|2 NLM
|
| 650 |
|
7 |
|a Amiloride
|2 NLM
|
| 650 |
|
7 |
|a 7DZO8EB0Z3
|2 NLM
|
| 650 |
|
7 |
|a Timolol
|2 NLM
|
| 650 |
|
7 |
|a 817W3C6175
|2 NLM
|
| 700 |
1 |
|
|a VandenBurg, M J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Isitt, V L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Currie, W J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 4(1984), 1 vom: 15., Seite 64-8
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:4
|g year:1984
|g number:1
|g day:15
|g pages:64-8
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 4
|j 1984
|e 1
|b 15
|h 64-8
|